Latest news

In view of the success of our previous shuttle sessions, which offered the opportunity to run efficacy studies in a cost-saving manner, we are planning a new shuttle on the orthotopic (OT) 4T1 mammary fat pad mouse model, which will be held in late March.

Modulation of the immune system function aiming at enhancing the responsiveness potential of immune cells is one of the current promising challenges in cancer immunotherapy. Modulating the mechanisms underlying immune cell activation is key for the development of innovative approaches to promote immune function and tackle tumor progression.

Explicyte is proud to announce the recent development and validation of our new syngeneic subcutaneously-implanted MCA-205 sarcoma tumor mouse model.

While known and validated as non-responsive to conventional immune checkpoint inhibitors, our OT syngeneic mammary tumor model, which represents an aggressive model of human breast carcinoma, is characterized by the presence of at least two types of tumor-infiltrating immunosuppressive cells – myeloid suppressive cells (MSC) and T regulatory cells (Treg).

In vivo glioma mouse model recapitulating key human glioblastoma characteristics provides an invaluable resource to assess novel immunotherapy-based strategies aiming at bolstering immune system functions to ultimately improve treatment outcome.

As in the previous shuttle session, Explicyte will plan a new shuttle on the CT26 tumor-bearing mouse model, which will be held in July.

 

We designed a specialized in vitro immune cell killing assay to assess your immunomodulatory candidate compounds/antibodies for their ability to enhance the killing immune response towards tumor cells.

To support your R&D program(s) in glioma, Explicyte has validated a syngeneic intracerebral mouse tumor model of Glioblastoma on which gold standard chemotherapy (Temozolomide, TMZ) and immunotherapy (CTLA4) has been validated.

To support your R&D program(s), we propose to explore and characterize the in vitro effect of your candidate compounds on human immune cells.

The Bordeaux-based antibody company ImmuSmol is launching today a range of preclinical services in the field of cancer immunotherapy under the brand Explicyte Immuno-Oncology

To test novel combination therapies aiming at increasing responses rates to immune checkpoint inhibitors, Explicyte has optimized a range of syngeneic mouse tumor models treated with anti-CTLA-4 or anti-PD-1/PD-L1 monoclonal antibodies.

This PLOS ONE paper, co-authored by Alban Bessède, CSO of Explicyte, demonstrates that the expression of tryptophan-degrading enzyme IDO1 is not strictly associated with L-Kynurenine production in breast and colorectal cancer tissues.